Multifunctional Hybridized Local and Charge‐Transfer Small Molecular Fluorophore for Imaging‐Guided Photodynamic Anticancer Therapy

Why It Matters

XSOTA merges diagnostic imaging and therapeutic action in a single molecule, streamlining photodynamic cancer treatment and reducing systemic side effects.

Key Takeaways

• XSOTA combines high fluorescence (89%) with strong ROS generation.
• Hybridized local‑charge transfer (HLCT) enables dual photophysical functions.
• Two‑photon absorption reaches 7000 GM, allowing deep tissue imaging.
• Nanoparticle formulation achieves >300 µm imaging depth in vivo.
• Photodynamic therapy suppresses tumors without observable organ toxicity.

Pulse Analysis

The emergence of hybridized local and charge‑transfer (HLCT) excited states marks a paradigm shift in molecular design for phototherapy. By coupling a dibenzothiophene‑S,S‑dioxide acceptor with a triphenylamine donor through a vinyl bridge, XSOTA balances locally excited (LE) and charge‑transfer (CT) characteristics. The LE component accelerates radiative decay, yielding an impressive 89.2% fluorescence quantum yield, while the CT facet promotes intersystem crossing, delivering a 56.3% ROS generation efficiency—metrics that surpass most conventional photosensitizers.

Beyond its photophysical prowess, XSOTA demonstrates practical utility when encapsulated in biocompatible nanoparticles. The formulation exhibits a two‑photon absorption cross‑section of 7000 GM, enabling deep‑tissue two‑photon fluorescence imaging of mouse vasculature at depths of 320 µm in bladder vessels and 350 µm in liver tissue. Such penetration surpasses typical one‑photon limits and facilitates real‑time visualization of tumor microenvironments, a critical advantage for precision oncology.

Clinically, XSOTA‑based nanoparticles achieve potent imaging‑guided photodynamic therapy, markedly inhibiting tumor growth while sparing major organs from toxicity. This dual‑function capability simplifies treatment protocols by eliminating the need for separate diagnostic and therapeutic agents. The success of XSOTA underscores the broader potential of HLCT fluorophores to accelerate the development of next‑generation theranostics, offering a scalable platform for targeted cancer interventions and expanding the toolbox for researchers pursuing integrated photomedicine solutions.